|6.66||-1.95||-22.65%||Vol 1.62M||1Y Perf -57.63%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.04 0.60%|
|Target Price||32.00||Analyst Rating||Strong Buy 1.13|
|Potential %||380.48||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-79/-93||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-82/-97||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-87/-94||Income Ranking||— -|
|Price Range Ratio 52W %||15.02||Earnings Rating||—|
|Market Cap||417.38M||Earnings Date||5th Aug 2022|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Q02 2020||-0.32||-4.43||-1 284.38|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.70|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||737.08K|
|Avg. Monthly Volume||634.43K|
|Avg. Quarterly Volume||493.23K|
AlloVir Inc. (NASDAQ: ALVR) stock closed at 6.66 per share at the end of the most recent trading day (a -22.65% change compared to the prior day closing price) with a volume of 1.62M shares and market capitalization of 417.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 53 people. AlloVir Inc. CEO is David Hallal.
The one-year performance of AlloVir Inc. stock is -57.63%, while year-to-date (YTD) performance is -48.53%. ALVR stock has a five-year performance of %. Its 52-week range is between 3.17 and 26.41, which gives ALVR stock a 52-week price range ratio of 15.02%
AlloVir Inc. currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 1.72, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.50%, a ROC of -66.79% and a ROE of -70.84%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from AlloVir Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.70 for the next earnings report. AlloVir Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for AlloVir Inc. is Strong Buy (1.13), with a target price of $32, which is +380.48% compared to the current price. The earnings rating for AlloVir Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AlloVir Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AlloVir Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 19.45, ATR14 : 0.85, CCI20 : 98.46, Chaikin Money Flow : -0.14, MACD : 0.77, Money Flow Index : 72.26, ROC : 44.47, RSI : 50.03, STOCH (14,3) : 52.80, STOCH RSI : 0.24, UO : 58.79, Williams %R : -47.20), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AlloVir Inc. in the last 12-months were: Agustin Melian (Sold 26 189 shares of value $627 360 ), Ann Leen (Sold 20 988 shares of value $465 559 ), Brett R. Hagen (Sold 1 839 shares of value $15 525 ), David Hallal (Sold 91 279 shares of value $425 335 ), Diana Brainard (Sold 29 135 shares of value $126 257 ), Ercem Atillasoy (Sold 10 289 shares of value $98 448 ), Jeffrey S. Bornstein (Buy at a value of $67 547), Jeroen B. Van Beek (Sold 91 602 shares of value $1 420 849 ), Morana Jovan-Embiricos (Sold 57 576 shares of value $1 427 646 ), Vikas Sinha (Sold 18 088 shares of value $143 377 )
Wed, 23 Mar 2022 13:58 GMT AlloVir (ALVR) Gets a Buy Rating from Leerink Partners- TipRanks. All rights reserved.
Tue, 18 Jan 2022 16:30 GMT Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), AlloVir (ALVR) and SI-Bone (SIBN)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.